Previous 10 | Next 10 |
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment o...
--No safety issues identified in Cohort 1 -- -- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled trial -- -- Topline data for Cohort 2 targeted for 1Q 2024; if positive, trial could p...
ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will pres...
2023-03-08 08:46:06 ET Intelligent Bio Solutions ( INBS ) -48% on proposed public offering . Castor Maritime ( CTRM ) -36% . Miromatrix Medical ( MIRO ) -32% on pricing $10M stock offering . United Natural Foods ( UNFI ) -22% on Q2...
2023-03-07 11:28:43 ET Gainers: Unicycive ( UNCY ) +52% . Bionomics ( BNOX ) +49% . Novo Integrated Sciences ( NVOS ) +37% . Protagonist Therapeutics ( PTGX ) +34% . Allakos ( ALLK ) +22% . Losers: Cara ( CARA ) -28...
2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...
2023-03-06 10:32:51 ET Following a ~65% rise in the previous session, clinical-stage biotech Kala Pharmaceuticals ( NASDAQ: KALA ) added another ~26% i n the morning hours Monday as Wall Street reacted to the company’s Q4 2022 results. Highlights of the financials...
2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...
2023-03-06 08:32:34 ET BridgeBio Pharma ( BBIO ) +57% Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events. TCR2 Therapeutics ...
Kala Pharmaceuticals press release ( NASDAQ: KALA ): Q4 GAAP EPS of -$7.97 misses by $1.42 . As of December 31, 2022, Kala had cash and cash equivalents of $70.5 million, compared to $52.4 million as of September 30, 2022. Based on its current plans, Kala anticipates that ...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...